To the Editor We read with great interest the article by Duan et al1 focusing on the assessment of the efficacy and safety profile of anti–programmed cell death 1 (PD-1) and anti–programmed cell death ligand 1 (PD-L1) immunotherapy by a mirror-principle meta-analytical method. With growing numbers of anti–PD-1 and anti–PD-L1 immunotherapy agents alone or in combination approved by the US Food and Drug Administration and other international regulatory agencies, and many similar drugs in various phases of clinical development, the goal of this study is indeed important for clinicians to select appropriate therapeutic regimens for patients with cancer. The authors of this study1 concluded that the efficacy of anti–PD-1 immunotherapy is superior to that of anti–PD-L1 immunotherapy with respect to overall and progression-free survival. In addition, there appears to be no significant difference in their respective safety profiles.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Wang T, Lee S, Feldman GM. Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer. JAMA Oncol. Published online April 30, 2020. doi:10.1001/jamaoncol.2020.0631
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: